Thus, our data suggest that when AOAH is lacking, excessive gut-derived LPS stimulates SREBP1 activation to promote de novo lipogenesis in the liver, contributing to more severe MASLD. Here, SREBF1 is linked to metabolic dysfunction-associated steatotic liver disease.